Kurs
-3,47%
Likviditet
0,05 MSEK
Prenumeration
Kalender
Tid* | ||
2025-11-05 | 08:00 | Kvartalsrapport 2025-Q3 |
2025-08-20 | 08:00 | Kvartalsrapport 2025-Q2 |
2025-05-07 | 08:00 | Kvartalsrapport 2025-Q1 |
2025-02-06 | 08:00 | Bokslutskommuniké 2024 |
2024-11-06 | - | Kvartalsrapport 2024-Q3 |
2024-08-21 | - | Kvartalsrapport 2024-Q2 |
2024-06-11 | - | X-dag ordinarie utdelning SPAGO 0.00 SEK |
2024-06-10 | - | Årsstämma |
2024-05-02 | - | Kvartalsrapport 2024-Q1 |
2024-02-07 | - | Bokslutskommuniké 2023 |
2023-11-03 | - | Kvartalsrapport 2023-Q3 |
2023-10-31 | - | Extra Bolagsstämma 2023 |
2023-07-31 | - | Kvartalsrapport 2023-Q2 |
2023-05-11 | - | X-dag ordinarie utdelning SPAGO 0.00 SEK |
2023-05-10 | - | Årsstämma |
2023-05-09 | - | Kvartalsrapport 2023-Q1 |
2023-02-02 | - | Bokslutskommuniké 2022 |
2022-11-08 | - | Kvartalsrapport 2022-Q3 |
2022-08-24 | - | Kvartalsrapport 2022-Q2 |
2022-05-19 | - | X-dag ordinarie utdelning SPAGO 0.00 SEK |
2022-05-18 | - | Årsstämma |
2022-04-27 | - | Kvartalsrapport 2022-Q1 |
2022-02-02 | - | Bokslutskommuniké 2021 |
2021-11-10 | - | Kvartalsrapport 2021-Q3 |
2021-08-24 | - | Kvartalsrapport 2021-Q2 |
2021-05-06 | - | X-dag ordinarie utdelning SPAGO 0.00 SEK |
2021-05-05 | - | Årsstämma |
2021-04-28 | - | Kvartalsrapport 2021-Q1 |
2021-02-02 | - | Bokslutskommuniké 2020 |
2021-01-15 | - | Extra Bolagsstämma 2021 |
2020-11-10 | - | Kvartalsrapport 2020-Q3 |
2020-08-24 | - | Kvartalsrapport 2020-Q2 |
2020-05-29 | - | X-dag ordinarie utdelning SPAGO 0.00 SEK |
2020-05-28 | - | Årsstämma |
2020-04-29 | - | Kvartalsrapport 2020-Q1 |
2020-01-30 | - | Bokslutskommuniké 2019 |
2019-11-13 | - | Extra Bolagsstämma 2019 |
2019-11-13 | - | Kvartalsrapport 2019-Q3 |
2019-05-09 | - | X-dag ordinarie utdelning SPAGO 0.00 SEK |
2019-05-08 | - | Årsstämma |
2019-04-25 | - | Kvartalsrapport 2019-Q1 |
2019-01-30 | - | Bokslutskommuniké 2018 |
2018-11-08 | - | Kvartalsrapport 2018-Q3 |
2018-08-27 | - | Kvartalsrapport 2018-Q2 |
2018-05-17 | - | X-dag ordinarie utdelning SPAGO 0.00 SEK |
2018-05-16 | - | Årsstämma |
2018-04-25 | - | Kvartalsrapport 2018-Q1 |
2018-02-14 | - | Bokslutskommuniké 2017 |
2017-11-08 | - | Kvartalsrapport 2017-Q3 |
2017-09-22 | - | Extra Bolagsstämma 2017 |
2017-08-25 | - | Kvartalsrapport 2017-Q2 |
2017-05-18 | - | X-dag ordinarie utdelning SPAGO 0.00 SEK |
2017-05-17 | - | Årsstämma |
2017-04-26 | - | Kvartalsrapport 2017-Q1 |
2017-02-14 | - | Bokslutskommuniké 2016 |
2016-11-08 | - | Kvartalsrapport 2016-Q3 |
2016-08-26 | - | Kvartalsrapport 2016-Q2 |
2016-05-12 | - | X-dag ordinarie utdelning SPAGO 0.00 SEK |
2016-05-11 | - | Årsstämma |
2016-04-27 | - | Kvartalsrapport 2016-Q1 |
2016-02-12 | - | Bokslutskommuniké 2015 |
2015-11-12 | - | Extra Bolagsstämma 2015 |
2015-11-06 | - | Kvartalsrapport 2015-Q3 |
2015-08-27 | - | Kvartalsrapport 2015-Q2 |
2015-05-06 | - | X-dag ordinarie utdelning SPAGO 0.00 SEK |
2015-05-05 | - | Årsstämma |
2015-04-29 | - | Kvartalsrapport 2015-Q1 |
2015-02-20 | - | Bokslutskommuniké 2014 |
2014-11-14 | - | Kvartalsrapport 2014-Q3 |
2014-08-27 | - | Kvartalsrapport 2014-Q2 |
2014-04-30 | - | X-dag ordinarie utdelning SPAGO 0.00 SEK |
2014-04-29 | - | Årsstämma |
2014-04-29 | - | Extra Bolagsstämma 2014 |
2014-04-29 | - | Kvartalsrapport 2014-Q1 |
2014-02-21 | - | Bokslutskommuniké 2013 |
2013-10-29 | - | Kvartalsrapport 2013-Q3 |
2013-08-29 | - | Kvartalsrapport 2013-Q2 |
2013-05-24 | - | Kvartalsrapport 2013-Q1 |
2013-04-25 | - | Årsstämma |
2013-02-22 | - | Bokslutskommuniké 2012 |
Beskrivning
Land | Sverige |
---|---|
Lista | First North Stockholm |
Sektor | Hälsovård |
Industri | Bioteknik |
The Annual General Meeting (AGM) of Spago Nanomedical AB (publ) was held today, June 10, 2024, at which the AGM resolved to approve the income statement and balance sheet for 2023 and discharge the Board members and the CEO from liability for the financial year 2023.
The following resolutions were also passed at the AGM:
Disposition of results and discharge from liability
In accordance with the board's proposal, no dividend will be paid and KSEK 19,366 are carried forward.
Election of board and board fees
The board shall consist of four ordinary members and no deputies. Hans Arwidsson, Kari Grønås Alan Raffensperger and Nicklas Westerholm were re-elected as directors of the board for the period until the end of the next AGM. Hans Arwidsson was re-elected as chairman of the board of directors.
Board fees for the period until the end of the next AGM shall be SEK 300,000 (unchanged) to the chairman of the board and SEK 150,000 (unchanged) to each of the other board members.
Election of auditor and auditor fee
In accordance with the Nomination Committee's proposal, BDO Mälardalen AB was re-elected as auditor for the period until the end of the AGM in 2025. Authorized Public Accountant Jörgen Lövgren will be primarily responsible for the audit. Fees to the auditor shall be paid in accordance with approved invoices.
Authorisation for the Board to resolve to issue new shares and/or warrants
For the period until the next AGM, the board was authorised to, on one or more occasions, resolve to issue new shares and/or warrants by cash payment, by contribution in kind or payment by way of set-off. By resolutions based on the authorization, issues of shares and/or warrants without deviation from the shareholders’ preferential rights may be up to, in total, as many shares as fall within the limits of the Articles of Association at the time of exercise of the authorisation. By resolutions based on the authorisation, with deviation from the shareholders’ preferential rights may be up to, in total, the number of shares corresponding to twenty (20) percent of the total number of outstanding shares in the company at the time of exercise of the authorisation the first time.
Resolution on amendment of the Articles of Association and reduction of the share capital
The AGM resolved, in accordance with the board's proposal, to amend the limits for the number of shares and the share capital in the Articles of Association (§ 4 and § 5). The AGM resolved further, in accordance with the board’s proposal, to reduce the company's share capital by SEK 31,337,658.54 for allocation to unrestricted shareholders’ equity. The reduction shall be made without redemption of shares, whereby the quota value is changed from SEK 0.10 to SEK 0.01. The reduction may not be implemented until permission has been obtained from the Swedish Companies Registration Office, or in disputed cases, from the district court.
For further information, please contact Mats Hansen, CEO Spago Nanomedical AB, +46 46 811 88, mats.hansen@spagonanomedical.se
Spago Nanomedical AB is a Swedish company in clinical development phase. The company´s development projects are based on a platform of polymeric materials with unique properties for more precise treatment and diagnosis of cancer and other debilitating diseases. Spago Nanomedical´s share is listed on Nasdaq First North Growth Market (ticker: SPAGO). For further information, see www.spagonanomedical.se.
FNCA Sweden AB is the Certified Adviser of the company.